New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

Although findings from a large retrospective study supports these positive effects of taking a GLP-1, it’s unclear whether ...

A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...

CHICAGO -- Plaque psoriasis drug deucravacitinib (Sotyktu) now looks likely to win a psoriatic arthritis (PsA) indication in ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.

An investigational monoclonal antibody drug targeting the PD-1 ligand on T cells was a winner in a phase II rheumatoid ...

Polypharmacy in RA patients is linked to increased drug interaction risks, especially with immunosuppressants, necessitating careful management and monitoring. Older age and multiple comorbidities are ...

Some people with psoriatic arthritis (PsA) may have a disease that is difficult to manage (D2M) or does not respond to ...

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has ...

Johnson & Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha ...

As physicians who treat life-threatening autoimmune disease, we are problem solvers, adept at prescribing diagnostic tests and medications to improve people’s health and quality of life. The problem ...